Stephen Evans-Freke "is Co-Founder and Managing General Partner of Celtic Therapeutics and Co-Founder and Managing Principal of Celtic Pharma, both global private equity funds focused on the pharmaceutical industry.
"Mr. Evans-Freke has been associated with the biotechnology industry for over 24 years, as an investment banker, asset manager, entrepreneur, company CEO, and venture capitalist. During the 1980s, he was lead investment banker to Genentech, AMGEN, Centocor, and a number of other leading biotech companies, structured and placed over $500 million of highly successful R&D partnership financing, and served on the Development Boards of these companies. During this period, Mr. Evans-Freke was President of PaineWebber Development Corporation and later a member of PaineWebber Inc.'s Board of Directors.
"In 1990 Mr. Evans-Freke left Wall St. and founded Selectide Corporation, one of the first combinatorial chemistry companies, for which he served as Chairman until its sale to Heochst in 1994. In 1991, Mr. Evans-Freke founded SUGEN, a drug discovery company focused on small molecule kinase and phosphatase inhibitors; he served as SUGEN Chairman and Chief Executive Officer through its IPO with Morgan Stanley in 1995 and until its sale to Pharmacia for $720 million in 1999. During this time, Mr. Evans-Freke was also a co-founder of Fibrogen, Inc. and Royalty Pharma AG.
"Subsequently, Mr. Evans-Freke served as an advisor to Pharmacia CEO Fred Hassan until 2001 and devoted himself to his personal venture investments until the founding of Celtic Pharma in 2004. He currently serves on the Boards of Cibus Genetics (Chairman), and International BioScience Managers, Ltd. Mr. Evans-Freke also serves on the 800-Year Anniversary Appeal Board of Cambridge University, from which he holds a degree in Law; the Cambridge Stem Cell Board; the Board of Governors of the U.S. Priory of the Order of St. John; and the Board of the Christopher and Dana Reeve Foundation. Mr. Evans-Freke is a citizen of the U.K. and Ireland and has been a resident of the U.S. for 28 years." 
- Director, Cross Match Technologies
Resources and articles
- Directors, Cross Match Technologies, accessed November 16, 2010.